20 Results

People

  1. Hamlin
    Hamlin
  2. Horwitz
    Horwitz
  3. Noy
    Noy
  4. Palomba
    Palomba
  5. Zelenetz
    Zelenetz
  6. Intlekofer
    Intlekofer
  7. Moskowitz
    Moskowitz
  8. Kumar
    Kumar
  9. Matasar
    Matasar
  10. Batlevi
    Batlevi

Groups

  1. Center for Hematologic Malignancies (20)
  2. Department of Medicine (20)
  3. GSK Faculty (20)
  4. Hematologic Malignancies Research (20)
  5. Hematologic Malignancies, Division of (20)
  6. Lymphoma (20)
  7. Population Sciences Research Program (20)
  8. Human Oncology and Pathogenesis Program (19)
  9. Survivorship Research (19)
  10. Sloan Kettering Institute Postdocs (15)
  1. "Center for Hematologic Malignancies"
  2. "Hematologic Malignancies Research"
  3. "Population Sciences Research Program"
  4. "David Straus"
  5. "Maria Palomba"
Formats
  1. Meeting Abstract (16)
  2. Journal Article (4)
Groups
  1. Center for Hematologic Malignancies (20)
  2. Department of Medicine (20)
  3. GSK Faculty (20)
  4. Hematologic Malignancies Research (20)
  5. Hematologic Malignancies, Division of (20)
  6. Lymphoma (20)

More Groups

People
  1. Andrew Zelenetz (20)
  2. Ariela Noy (20)
  3. David Straus (20)
  4. Maria Palomba (20)
  5. Paul Hamlin (20)
  6. Steven Horwitz (20)

More People

Years
  1. 2023 (4)
  2. 2022 (3)
  3. 2021 (1)
  4. 2020 (3)
  5. 2019 (2)
  6. 2018 (1)

More Years

Publications
  1. Blood (12)
  2. Hematological Oncology (3)
  3. Blood Advances (2)
  4. Journal of Clinical Oncology (2)
  5. Blood Cancer Journal (1)
Publishers
  1. American Society of Hematology (14)
  2. Wiley Blackwell (3)
  3. American Society of Clinical Oncology (2)
  4. Nature Publishing Group (1)

Results (20)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
    Journal Article

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Moskowitz, A. J.; Stuver, R. N.; Maccaro, C. R.; Galasso, N.; Chang, T.; Khan, N.; Aypar, U.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Retrospective characterization of nodal marginal zone lymphoma
    Journal Article

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation
    Meeting Abstract

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Favorable outcomes among patients with T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era
    Meeting Abstract

    Robin, E. T.; Drill, E.; Batlevi, C. L.; Caron, P.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; Joffe, E.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save